Published • loading... • Updated
Living with early Parkinson's disease? A clinical trial is exploring a more personalized approach to treatment
Researchers are testing whether blocking LRRK2 can slow progression in a group that includes about 30% of people with Parkinson's disease, Dr. Danielle Larson said.
- Researchers are enrolling early-stage Parkinson disease patients in the Phase 2 NEULARK clinical trial, which investigates whether inhibiting the LRRK2 protein can slow disease progression rather than just managing symptoms.
- Current treatments for Parkinson disease focus primarily on managing symptoms, leaving patients like Hindhaugh hoping for new options that address the underlying biological drivers of this progressive brain disorder.
- Approximately 30% of people with Parkinson disease have LRRK2 pathway overactivity, which may lead to damaged brain cells, explained Dr. Danielle Larson, a movement disorders specialist and NEULARK trial investigator.
- Eligible participants aged 40 to 80 who have not yet started medication can access investigational genetic testing through a simple at-home saliva test, available at no cost to determine eligibility.
- The NEULARK trial is exploring a personalized approach by studying biological differences contributing to Parkinson, using smartphone-based technology to capture daily symptom fluctuations that could be missed during clinic visits.
Insights by Ground AI
30 Articles
30 Articles
Newark Post+29 Reposted by 29 other sources
Living with early Parkinson's disease? A clinical trial is exploring a more personalized approach to treatment
(BPT) - When Tony Hindhaugh was diagnosed with Parkinson's disease at age 55, he learned that there are currently no approved therapies that slow the progression of the disease. Current treatments focus primarily on managing symptoms of the progressive brain…
Coverage Details
Total News Sources30
Leaning Left1Leaning Right1Center24Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
